Search

The current meta-analysis was conducted aiming to explore the association between pre-therapy CRP and DLBCL survival outcomes. We retrieved previously published studies available from PubMed, EMBASE, Web of Science, The Cochrane Library, Wanfang databases, and China National Knowledge Infrastructure databases by June 2017. A total of 12 studies composed of 3000 patients were included in this study according to our selection criteria. The pooled HRs of elevated pre-therapy CRP were 2.66 (95% CI = 1.95-3.64, p < .001) for OS while 2.19 (95% CI = 1.72-2.78, p < .001) for PFS. Sensitivity analysis and subgroup analysis indicated that CRP remained a prognostic biomarker for OS and PFS. The pooled HR was 3.01 (95% CI = 2.38-3.81, p < .001) for OS if excluding 3 heterogeneous studies, and the heterogeneity decreased from 59.6% to 11.2%. Our study revealed that pre-therapy CRP can be a potential prognostic marker for patients with DLBCL. [ABSTRACT FROM AUTHOR]

Objective: The aim of this study was to assess the prognostic value of admission immune cell levels in the peripheral blood in determining outcomes in patients with TBI. Method: We studied 141 adult patients with mild-to-severe TBI (Glasgow Coma Scale (GCS) 3-15). Patient outcome was assessed using the Extended Glasgow Outcome Scale (GOSE) at 6 months post-injury. The area under the curve (AUC) was used to evaluate the predictive ability of immune cell levels. Uni- and multivariate analyses were performed to assess the independent predictors of 6-month outcome. Results: We found that admission monocyte count was not only a better predictor (AUC = 0.778; 95% confidence interval (CI), 0.679-0.858) of favourable outcomes (GOSE 5-8) at 6 months post-injury than were admission haemoglobin (AUC = 0.629; 95% CI, 0.522-0.728) and blood glucose (AUC = 0.616; 95% CI, 0.508-0.716) levels for patients with moderate-to-severe TBI (GCS ≤ 12), but also an independent predictor of 6-month outcome (adjusted odds ratio, 1.35; 95% CI, 1.10-1.65; p = 0.004). Conclusions: The present study suggests that an increase in admission monocyte count is correlated with a favourable 6-month outcome in patients with moderate-to-severe TBI. [ABSTRACT FROM AUTHOR]

Objective: To prospectively investigate the predictive value of initial intracranial pressure (ICP) for refractory intracranial hypertension and outcomes in persons with diffuse traumatic brain injury (TBI). Methods: A prospective observational study was conducted in 107 adult persons with diffuse TBI (Marshall CT Class II-IV). Initial ICP was defined as the first ICP recorded in the operating room. Refractory intracranial hypertension was defined as ICP increases to more than 30 mmHg and/or reduces in cerebral perfusion pressure to less than 60 mmHg for a period longer than 15 minutes and failure to respond to the maximum medical treatment. Baseline demographics and injury-specific data were recorded. Multiple logistic regression models were used to determine independent risk factors for refractory intracranial hypertension and unfavourable outcomes. A receiver-operating characteristic (ROC) curve was then drawn. Results: The initial ICP allowed for a better refractory intracranial hypertension prediction (ROC area = 0.868; 95% CI = 0.799-0.937) than the Marshall Classification (ROC area = 0.670; 95% CI = 0.569-0.772) or Rotterdam Classification scores (ROC area = 0.679; 95% CI = 0.577-0.780). An initial ICP value higher than 20 mmHg had 83% sensitivity and 83% specificity, whereas an initial ICP value higher than 25 mmHg had 64% sensitivity and 92% specificity for refractory intracranial hypertension. A multivariable logistic regression model showed that any 5 mmHg pressure increase in a patient with initial ICP led to 2.884-times higher odds of refractory intracranial hypertension (95% CI = 1.893-4.395; p < 0.001). Head Abbreviated Injury Scale score, initial Glasgow Coma Scale (GCS) and initial GCS motor scores were not predictive of refractory intracranial hypertension ( p > 0.05). Conclusion: For persons with diffuse TBI, the initial ICP provides great prognostic discrimination and is an independent predictor of refractory intracranial hypertension. [ABSTRACT FROM AUTHOR]